J Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
|
|
- Rhoda Dean
- 5 years ago
- Views:
Transcription
1 VOLUME 5 NUMBER 8 OCTOBER 7 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Global Histone Modifications Predict Prognosis of Resected Non Small-Cell Lung Cancer Fabrice Barlési, Giuseppe Giaccone, Marielle I. Gallegos-Ruiz, Anderson Loundou, Simone W. Span, Pierre Lefesvre, Frank A.E. Kruyt, and Jose Antonio Rodriguez From the Departments of Medical Oncology and Pathology, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; and Statistics Department, and Department of Thoracic Oncology, Université de la Méditerranée, Assistance Publique Hôpitaux de Marseille, Marseille, France. Submitted February, 7; accepted July, 7. Authors disclosures of potential conflicts of interest and author contributions are found at the end of this article. Address reprint requests to Giuseppe Giaccone, MD, PhD, Medical Oncology Branch, CCR, National Cancer Institute, Center Dr, Bldg, Room N6, Bethesda MD 89-9; giacconeg@mail.nih.gov. 7 by American Society of Clinical Oncology 7-8X/7/58-58/$. DOI:./JCO A B S T R A C T Purpose Epigenetic modifications may contribute to the development and progression of cancer. We investigated whether epigenetic changes involving multiple histones influence prognosis of non small-cell lung cancer (NSCLC) patients. Patients and Methods We used immunohistochemistry to assess histone lysine dimethylation (HKdiMe), and acetylation of histone A lysine 5 (HAK5Ac), histone B lysine, histone lysine 9 (HK9Ac), and histone lysine 8 in resected tumor samples of 8 NSCLC patients. Data were analyzed using a recursive partitioning analysis (RPA). Results The RPA classified the patients into seven distinct prognostic groups based on TNM stage (first node), histology, and histone modifications: HKdiMe ( or 85% tumor cells), HK9Ac ( or 68% tumor cells), and HAK5Ac ( or 5% tumor cells). The seven groups were associated with significantly different disease-free (P.) and overall survival (P.). Interestingly, the four groups determined by stage I patients (below the first node) displayed dramatic differences in survival (median, months in adenocarcinoma patients with HK9Ac 68% v 7 months in nonadenocarcinoma patients with HKdiMe 85%). A Cox model retained age and RPA groups as the sole independent factors significantly influencing overall survival. Conclusion The prognostic influence of epigenetic changes involving multiple histones, in particular HA and H, is greater in early NSCLC, and evaluation of these changes may help in selecting early-stage NSCLC patients for adjuvant treatment. Our observations provide a rationale for the use of a combination of standard chemotherapy with drugs interacting with histone modifications, such as histone deacetylase inhibitors. J Clin Oncol 5: by American Society of Clinical Oncology INTRODUCTION Lung cancer is the leading cause of cancer-related death worldwide, with more than. million deaths each year. Non small-cell lung cancer (NSCLC) represents approximately 8% of all lung cancers. The poor prognosis of NSCLC is due mainly to late diagnosis, inasmuch as only approximately % to % of patients are eligible for tumor resection. Despite surgery, recurrences are common even in early NSCLC, occurring in up to two thirds of patients. Although pathologic staging is the most important prognostic factor for patients who undergo resection, there are broad differences within stages, 5 which are due to the different biologic behavior of the tumor. Thus, the identification of biologic markers might help to assess more precisely the prognosis and to address more clearly the use of adjuvant therapy. Several markers have been identified that have prognostic implication in resected NSCLC. 6,7 However, none is used in routine practice because of conflicting results reported (reviewed by Zhu et al 8 ), technological challenges, or both. In addition to genetic alterations, epigenetic changes may contribute to the development and progression of cancer and leukemia. 9 The term epigenetics refers to a number of molecular mechanisms that regulate gene expression without changing the DNA sequence. These mechanisms include alterations in the methylation status of DNA, covalent modification of histone tails, chromatin remodeling, and micrornas. - Epigenetic deregulation may affect several aspects of tumor cell biology, including cell growth, differentiation, and cell death, and thereby it is likely to 58
2 Global Histone Modifications in Predicting Survival in NSCLC be linked to patient prognosis. Most studies on the role of epigenetic alterations in cancer have focused on the aberrant pattern of DNA methylation; in fact, the potential targeting of DNA methylation as a therapeutic approach for lung cancer treatment is being evaluated. In comparison to DNA methylation, other mechanisms of epigenetic regulation, such as the methylation and acetylation of histones, are less well characterized. However, histone modifications together with DNA methylation seem to have a vital role in organizing nuclear architecture, which in turn is involved in regulating transcription and other nuclear processes (reviewed by Esteller 5 ). A recent report identified the global pattern of histone modification as predictor of the risk of recurrence in prostate cancer patients. 6 By applying an unsupervised clustering algorithm, patients were grouped according to the histone H and H modification patterns determined by immunohistochemistry in a tumor tissue microarray. Using this approach, the authors showed that the groups identified were clinically relevant, and provided prognostic information independently of classical prognostic factors, such as tumor grade, preoperative prostate-specific antigen levels, or capsule invasion. In terms of clinical applicability, patients with a lower risk of recurrence could also be identified by examining a single modification, the dimethylation of histone H lysine (HK). We investigated the pattern of global histone modification as a potential prognostic marker in resected NSCLC. We used immunohistochemistry to evaluate the level of HK dimethylation (HKdiMe), 6 and the acetylation of four additional histone residues, including histone A lysine 5 (HAK5Ac), histone B lysine (HBKAc), histone lysine 9 (HK9Ac), and histone lysine 8 (HK8Ac). We analyzed the relationship between epigenetic changes involving multiple histones and patient prognosis using a recursive partitioning analysis (RPA), with overall survival as the primary end point. PATIENTS AND METHODS Patients Tumor samples of 8 patients with early-stage NSCLC (stage I to IIIA) were included in the present study. Patients underwent radical thoracic surgery of primary tumor (lobectomy or pneumonectomy) and regional lymph nodes at the Vrije Universiteit Medical Center (Amsterdam, the Netherlands), between January 988 and December 995. Patients did not receive any preoperative or postoperative treatment. The histopathologic features of the tumor specimens were classified according to the WHO criteria. 7 The TNM staging was determined according to the 997 International Union Against Cancer classification (Table ). Institutional review board approval was obtained to use archived material for research purposes. Immunohistochemistry We used specific rabbit polyclonal antibodies to detect five different histone modifications, including HKdiMe (Abcam, Cambridge, United Kingdom) and HAK5Ac, HBKAc, HK9Ac, and HK8Ac (all from Cell Signaling Technology, Danvers, MA). The use of antibodies was optimized and, once an appropriate dilution and incubation time had been determined, a whole-tissue section of each tumor was stained with each antibody, using standard two-step indirect immunohistochemistry. After deparaffinization in xylenes, the sections were rehydrated in graded alcohols. Endogenous peroxidase was quenched with.% hydrogen peroxide in methanol at room temperature ( C). The sections were placed in a C solution of. M sodium citrate buffer (ph 6.) for antigen retrieval. Primary antibodies were applied as follows: HKdiMe, : for minutes at room temperature; HAK5Ac, :5 overnight; HBKAc, :5 overnight; HK9Ac, : overnight; HK8Ac, :5 overnight). Detection was accomplished with the Dako Characteristic Table. Patient Characteristics (N ) % Age, years Sex Male 9 8 Female 7 Histology Squamous cell carcinoma 66 5 Adenocarcinoma 8 9 Large-cell carcinoma 8 Differentiation grade Well differentiated Moderately differentiated Poorly differentiated Tumor status T 6 T 9 68 T 8 6 Nodal status N 98 7 N 7 N 7 5 Stage IA 5 9 IB 66 5 IIA 6 IIB 7 IIIA 8 6 (Carpinteria, CA) Envision System, followed by chromogen detection with diaminobenzidine. The sections were counterstained with hematoxylin, dehydrated, and mounted. Negative controls were whole-tissue sections stained in the absence of the primary antibody. A semiquantitative assessment of antibodies staining on whole-tissue sections was performed independently by two observers (F.B. and P.L.), who were blinded to all clinicopathologic variables. In case of discordance, both observers defined the final score of the sample together. The score of each whole-tissue section was based on the frequency, regardless of intensity, of cells with positive nuclear staining (range, % to %) within the tumor. Statistical Analysis Follow-up data were updated in February 5. The overall survival time was defined as the time from the date of surgery to date of death as a result of any cause. Patients who were alive at the date of the last follow-up were censored on that date plus one day. Probability of survival was estimated using the Kaplan-Meier method. Differences in survival were tested by means of the log-rank test. To test whether variables differed across groups, the test or Fisher s exact test was used according to test condition. A Cox proportional hazards model was performed to establish independent factor(s) for survival. Statistical significance was defined as P.5. All of the tests are two sided. Statistical analysis was performed using the SPSS software package, version. (SPSS Inc, Chicago, IL). An RPA 8 was performed to test how histone modifications might influence prognosis. In RPA, a classification tree is constructed that provides decision rules for assigning a sample to a category based on a series of sequential decisions. At each stage, a single predictor is used, and depending on whether the value of the predictor is above or below a selected cutoff value, the sample is assigned to a left or right node. Each of the resulting nodes is then analyzed using the same procedure, although different predictor variables and cutoff values may be used. The cutoff value is selected 59
3 Barlési et al A F > 9 B G C D H I > > 9 Fig. Immunohistochemical analysis of NSCLC tumor samples. Representative examples of positively stained sections (original magnification ) for HKdiMe (A), HAK5Ac (B), HBKAc (C), HK9Ac (D), and HK8Ac (E), from different patients; distribution of staining for HKdiMe (F), HAK5Ac (G), HBKAc (H), HK9Ac (I), and HK8Ac (J) antibodies across all the tumor samples. The y-axis represents the number of samples showing positive staining for the indicated percentage of cells stained (x-axis), scored under highpowered field. 5 E J > > 9 6 JOURNAL OF CLINICAL ONCOLOGY
4 Global Histone Modifications in Predicting Survival in NSCLC to maximize the likelihood-ratio statistic for the test that the probability of a particular sample belonging to a given group is independent of whether the predictor of that sample is above or below the cutoff value. Thus, the cutoff value is chosen to make samples above and below the cutoff value as different as possible with respect to classification. This procedure continues until the data in each node are sufficiently well discriminated or until there are too few data in any node to support additional analysis. RESULTS Samples from six patients were not assessable because of insufficient tumor tissue, leaving samples available for analysis. Major clinical and biologic characteristics of these patients are summarized in Table. Immunohistochemical Study of HKdiMe, HAK5Ac, HBKAc, HK9Ac, and HK8Ac The expression of HKdiMe, HAK5Ac, HBKAc, HK9Ac, and HK8Ac was nuclear rather than diffuse, sometimes with a granular staining pattern (Fig A to E). Some slides showed a low level of heterogeneity in the tumor cells staining. The number of tumor cells stained positive by the anti-hkdime, -HAK5Ac, -HBKAc, -HK9Ac, and -HK8Ac ranged from % to % (mean, 57%, 68%, 8%, %, and 6%, respectively; Figs E and F). The overall median expression of HKdiMe, HAK5Ac, HBKAc, HK9Ac, and HK8Ac was 75%, %, %, 5%, and 8%, respectively. The HKdiMe, HAK5Ac, HBKAc, HK9Ac, and HK8Ac histone modifications were rarely associated within the same tumor sample, with the exception of HK9Ac and HK8Ac (Pearson s correlation coefficient, r.9; P.5). HKdiMe expression was correlated with International Union Against Cancer stage (Pearson s correlation coefficient, r.8; P.). No additional relationship was shown between HKdiMe, HAK5Ac, HBKAc, HK9Ac, and HK8Ac stainings and patient clinical characteristics. Global Histone Modification Patterns and Survival The median follow-up was 8 months. One hundred two patients were dead at the time of this analysis, including three lost to follow-up, and were alive, including two patients alive with a local relapse of their disease. The median overall survival and disease-free survival of the whole population was 8 months (95% CI, to months) and months (95% CI, to months), respectively. The RPA classified patients into seven distinct prognostic groups (Fig and Table ). The first prognostic node was based on pathologic tumor stage, with those with stage II or higher having a worse survival than those with stage I (Fig ). Patients with a pathologic tumor stage II or higher were divided into two additional prognostic groups on the basis of their pathologic stage. No other variable could segregate patients with a pathologic tumor stage III. In contrast, pathologic tumor stage II patients were classified into two separate groups by a third node based on acetylation of HAK5. Patients whose tumors expressed HAK5Ac in less than 5% of tumor cells had a worse survival compared with patients whose tumors had more than 5% of cells expressing HAK5Ac (Fig ). Within the stage I patients, the RPA also provided a second node based on histology. Stage I patients with an adenocarcinoma had a worse prognosis than those with a large-cell or squamous cell carcinomas. RPA incorporated histone modifications as a third node for stage I patients. Dimethylation of HK significantly influenced survival of stage I patients with large-cell or squamous cell carcinomas, with a greater survival for patients whose tumor expressed high levels ( 85% of tumor cells) of HKdiMe (group v group ). Moreover, acetylation of HK9 significantly influenced survival of stage I patients with adenocarcinomas, with a greater survival for patients whose tumors expressed lower levels ( 68% of tumor cells) of HK9Ac (group v group ). The seven groups defined the terminal classification of the patients available and were associated with different disease-free (P.) and overall survival (P.; Table and Fig ). Stage I scc/lcc HKdi Me Histology adc HK9Ac HAK5Ac 85% < 85% < 68% 68% 5% < 5% Stage II Group Group Group Group Group 5 Group 6 Group 7 n = 6 n = 6 n = n = 7 n = 9 n = n = 8 Yes No Yes No Fig. Recursive partitioning analysis (RPA) results individualizing seven different prognostic groups among the samples from non small-cell lung cancer patients who underwent resection included in our study. Each node, where the branches of the RPA tree bifurcate, divides patients according to whether the value of a specific feature (predictor) is above or below a selected cutoff value. The first node is represented by the pathologic stage. In stage I patients, histologic subtype provides the second node, and histone modifications (eg, the percentage of cells stained positively for histone H lysine dimethylation [HKdiMe] or for histone lysine 9 acetylation [HK9Ac]) provide the third node. HAK5Ac, histone A lysine 5 acetylation. 6
5 Barlési et al Table. Median Disease-Free and Overall Survival of the Different Groups of NSCLC Patients Who Underwent Resection Established by the Recursive Partitioning Analysis found to influence overall survival significantly and independently (Table ). Group No. of Patients Disease-Free Survival Overall Survival Median (months) 95% CI Median (months) 95% CI DISCUSSION to 75 7 to to 6 to to to to8 to 5 9 6to7 to to 5 to to8 to8 Abbreviation: NSCLC, non small-cell lung cancer. P.. A Cox proportional hazards model including age, sex, pathologic stage, histology, and RPA groups was analyzed to assess independent factors for overall survival. Sex, pathologic stage, and histology were not retained by the model. Conversely, age and RPA groups were In addition to genetic alterations, epigenetic modifications have been implicated in carcinogenesis and cancer development in various types of solid cancer and hematologic malignancies. 9- Epigenetic modifications seem to have different importance in the development of different tumor types. During prostate carcinogenesis, for example, epigenetic changes are so frequent that they allow discrimination between normal and neoplastic tissue with a specificity of up to %. 9, Furthermore, the prognostic value of certain epigenetic alterations in prostate cancer, breast cancer, and leukemia have been established. Conversely, the contribution of epigenetic changes to lung carcinogenesis seems to be less clear. In this study, the pattern of expression and biologic relevance of some histone modifications were analyzed for the first time in NSCLC patients who had undergone resection. Relevant features of the histone modification patterns A B C D Fig. (A) Overall survival and (B) disease-free survival of the different groups of non small-cell lung cancer patients who underwent resection established by the recursive partitioning analysis (RPA). (C) Overall survival and (D) disease-free survival of the different groups of stage I only patients established by the RPA. 6 JOURNAL OF CLINICAL ONCOLOGY
6 Global Histone Modifications in Predicting Survival in NSCLC Table. Multivariate Analysis Using a Cox Proportional Hazards Model Including the Groups Determined by the RPA, Pathologic Stage, Histology, Sex, and Age Variable HR 95% CI P Group Reference.99. to to to to to to 9.9. Sex: male v female.76. to..86 Histology LCC v SCC.86.5 to.5.6 LCC v ADC..5 to Age 7 years.. to.6.7 NOTE. Pathologic stage was not retained by the model because of colinearity with RPA group variable (linearly dependent covariables). Abbreviations: RPA, recursive partitioning analysis; LCC, large-cell carcinoma; SCC, squamous cell carcinoma; ADC, adenocarcinoma. observed in our series include the predominant but not exclusive detection in neoplastic cells in relation to normal lung epithelium, and a characteristic granular staining pattern. The nontumor exclusive staining as well as the low level of heterogeneity noted in some samples is not surprising, giving the role of histone modifications in cell growth, differentiation, and cell death. We show that histone HKdiMe as well as histone HAK5Ac and HK9Ac influenced overall and disease-free survival of NSCLC patients who had undergone resection, suggesting that the role of epigenetic modifications in lung carcinogenesis should be explored further. The postoperative management of stage I NSCLC is still a matter of debate. Although surgery alone represents the standard of care for stage IA patients, conflicting results have been presented regarding the use of adjuvant chemotherapy for stage IB patients., Despite the relatively early diagnosis, a substantial percentage of stage IB patients will experience relapse and succumb to their disease; 5-year survival of pathologic stage IB treated by surgery alone is 57%. Stage I represents a heterogeneous group as demonstrated by Potti et al. 5 On the basis of a gene-expression profile termed lung metagene, these authors were able to predict recurrence for individual stage I patients significantly better than did clinical prognostic factors, and they identified a subgroup of stage IA patients with a high risk of recurrence. Whether these data provide sufficiently robust and reproducible information regarding the use of adjuvant chemotherapy in early-stage NSCLC remains to be established. On the basis of our results, histone modifications, especially methylation and acetylation of histone H, should also be considered in the attempt to better define prognostic subgroups of stage I NSCLC patients. Interestingly, several drugs interacting with histone modifications have been developed in recent years, such as the histone deacetylase inhibitors. Several structurally distinct classes of histone deacetylase inhibitors have been developed 5 and are being tested in clinical trials. A significant antitumor activity was reported in several tumor types, including NSCLC, for some of these agents, such as pivaloyloxymethyl butyrate and CI-99. 6,7 Numerous additional studies are still ongoing and results are awaited. In our study we used the tool of RPA to assess the prognostic value of several histone modifications in relation to known prognostic features in resected NSCLC. There are several methodologies to investigate the potential prognostic value of clinical and biologic features. Multidimensional scaling, as used by Seligson et al, 6 is a set of data analysis techniques that displays the structure of distance-like data as a geometric picture, on which multiple subsequent analyses usually are performed. 8 Conversely, the central result of RPA is a tree, in which the data are organized (partitioned) into nodes (leaves) along branches; data that are more similar according to specified criteria (eg, overall survival) tend to be localized into the same nodes, whereas more dissimilar data tend to occupy different nodes. 9 Therefore, no additional analysis is needed. Furthermore, RPA is particularly well suited when the connection between the variables is complex, and even when there is missing information. For these reasons we used RPA in this study instead of multidimensional scaling. The selection of ptnm stage, a well-known prognostic factor in NSCLC, as the first node supports the validity of the method. Therefore, the histone modifications retained by the RPA should be regarded as valuable new prognostic factors in resected NSCLC patients; in particular, histone HKdiMe and HK9Ac, which are related to prognosis of those patients with resected stage I NSCLC. However, how these specific epigenetic modifications or combination of modifications affect the expression of particular genes or tumor behavior remains to be fully understood. One possibility is that expression of critical genes may be modulated differently by different epigenetic changes, and this hypothesis should be evaluated further by comparative transcriptional analysis of tumors characterized by different patterns of histone modifications. In conclusion, our results highlight the role of epigenetic changes involving multiple histones in lung cancer, identifying possible useful markers for selection of early-stage (especially stage I) NSCLC patients for adjuvant therapy. Our observations provide a rationale for studies of standard chemotherapy, drugs interacting with histone modifications, or combinations of both for the management of these patients. AUTHORS DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The author(s) indicated no potential conflicts of interest. AUTHOR CONTRIBUTIONS Conception and design: Giuseppe Giaccone, Anderson Loundou, Simone W. Span, Frank A.E. Kruyt, Jose Antonio Rodriguez Financial support: Giuseppe Giaccone Administrative support: Giuseppe Giaccone, Jose Antonio Rodriguez Provision of study materials or patients: Giuseppe Giaccone, Simone W. Span, Jose Antonio Rodriguez Collection and assembly of data: Fabrice Barlési, Giuseppe Giaccone, Marielle I. Gellegos-Ruiz, Simone W. Span, Pierre Lefesvre, Frank A.E. Kruyt, Jose Antonio Rodriguez Data analysis and interpretation: Fabrice Barlési, Giuseppe Giaccone, Anderson Loundou, Frank A.E. Kruyt, Jose Antonio Rodriguez Manuscript writing: Fabrice Barlési, Giuseppe Giaccone, Anderson Loundou, Frank A.E. Kruyt, Jose Antonio Rodriguez Final approval of manuscript: Fabrice Barlési, Giuseppe Giaccone, Marielle I. Gellegos-Ruiz, Anderson Loundou, Simone W. Span, Pierre Lefesvre, Frank A.E. Kruyt, Jose Antonio Rodriguez 6
7 Barlési et al REFERENCES. American Cancer Society: Cancer Facts and Figures 6. Atlanta, GA, American Cancer Society, 6. Travis W, Travis LB, Devesa SS: Lung cancer incidence and survival by histologic type. Cancer 75:9-, 995 (suppl ). Fry W, Phillips JL, Menck HR: Ten-year survey of lung cancer treatment and survival in hospitals in the United States. Cancer 86: , 999. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest :7-77, Potti A, Mukherjee S, Petersen S, et al: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 55:57-58, 6 6. Thomas P, Doddoli C, Thirion X, et al: Stage I non-small cell lung cancer: A pragmatic approach to prognosis after complete resection. Ann Thorac Surg 7:65-7, 7. Lu C, Soria JC, Tang X, et al: Prognostic factors in resected stage I non-small-cell lung cancer: A multivariate analysis of six molecular markers. J Clin Oncol :575-58, 8. Zhu CQ, Shih W, Ling CH, et al: Immunohistochemical markers of prognosis in non-small cell lung cancer: A review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 59:79-8, 6 9. Lund AH, van Lohuizen M: Epigenetics and cancer. Genes Dev 8:5-5,. Gibbons RJ: Histone modifying and chromatin remodeling enzymes in cancer and dysplastic syndromes. Hum Mol Genet :R85-R9, 5. Bhalla KN: Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol :97-99, 5. Esteller M: The necessity of a human epigenome project. Carcinogenesis 7:-5, 6. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet :5-8,. Digel W, Lubbert M: DNA methylation disturbances as novel therapeutic target in lung cancer: Preclinical and clinical results. Crit Rev Oncol Hematol 55:-, 5 5. Esteller M: Cancer epigenomics: DNA methylome and histone-modification maps. Nat Rev Genet 8:86-98, 7 6. Seligson DB, Horvath S, Shi T, et al: Global histone modification patterns predict risk of prostate cancer recurrence. Nature 5:6-66, 5 7. Travis WD, Colby TV, Corrin B, et al: In collaboration with pathologists from countries: World Health Organization International Histological Classification of Tumours Histological typing of lung and pleural tumours (ed ). Berlin, Germany, Springer- Verlag, Zhang HP, Singer B: Recursive Partitioning in the Health Sciences. New York, NY, Springer, Jerónimo C, Henrique R, Hoque MO, et al: Quantitative RARbeta hypermethylation: A promising prostate cancer marker. Clin Cancer Res : -,. Tokumaru Y, Harden SV, Sun DI, et al: Optimal use of a panel of methylation markers with GSTP hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res :558-55,. Kim H, Kwon YM, Kim JS, et al: Tumorspecific methylation in bronchial lavage for the early detection of non small-cell lung cancer. J Clin Oncol :6-7,. Strauss GM, Herdon J, Maddaus MA, et al: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 96. J Clin Oncol :6s, (suppl; abstr 79). Strauss GM, Herndon JE, Maddaus MA, et al: Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 96. J Clin Oncol :65s, 6 (suppl; abstr 77). Gilbert J, Gore S, Herman J, et al: The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res : , 5. Lindemann RK, Gabrielli B, Johnstone RW: Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle : , 6. Reid T, Valone F, Libera W, et al: Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer 5:8-86, 7. Pauer L, Olivares J, Cunningham C, et al: Phase I study of oral CI-99 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest : , 8. Young FW, Hamer RM: Theory and Applications of Multidimensional Scaling. Hillsdale, NJ, Erlbaum Associates, Young SS, Ge N: Recursive partitioning analysis of complex disease pharmacogenetic studies: I Motivation and overview. Pharmacogenomics 6:65-75, 5. Zaykin DV, Young SS: Large recursive partitioning analysis of complex disease pharmacogenetic studies: II Statistical considerations. Pharmacogenomics 6:77-89, 5 6 JOURNAL OF CLINICAL ONCOLOGY
The Global Histone Modification Patterns of Osteosarcoma
The Korean Journal of Pathology 2011; 45: 146-150 DOI: 10.4132/KoreanJPathol.2011.45.2.146 The Global Histone Modification Patterns of Osteosarcoma Sung-Im Do Sung-Jig Lim 1 Youn-Wha Kim Liliana G. Olvi
More informationGlobal Histone Modification Patterns as Prognostic Markers to Classify Glioma Patients
Research Article Global Histone Modification Patterns as Prognostic Markers to Classify Glioma Patients Cancer Epidemiology, Biomarkers & Prevention Bo-lin Liu 1, Jin-xiang Cheng 1, Xiang Zhang 1, Rui
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationPrognostic factors in curatively resected pathological stage I lung adenocarcinoma
Original Article Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Yikun Yang 1, Yousheng Mao 1, Lin Yang 2, Jie He 1, Shugeng Gao 1, Juwei Mu 1, Qi Xue 1, Dali Wang 1,
More informationCell Culture. The human thyroid follicular carcinoma cell lines FTC-238, FTC-236 and FTC-
Supplemental material and methods Reagents. Hydralazine was purchased from Sigma-Aldrich. Cell Culture. The human thyroid follicular carcinoma cell lines FTC-238, FTC-236 and FTC- 133, human thyroid medullary
More informationVisceral pleural involvement (VPI) of lung cancer has
Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,
More informationThe Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC)
The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC) Disclosure None Background Torino, Italy LCNC Rare tumor (2% to 3% all resected primary lung cancers) Preoperative
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationCorrelation between survivin expression and prognosis in non-small cell lung cancer
Respiratory Medicine (2006) 100, 2220 2226 Correlation between survivin expression and prognosis in non-small cell lung cancer Sükran Atikcan a, Ebru Ünsal a,, Funda Demirag b, Deniz Köksal a, Aydın Yilmaz
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationOriginal Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical outcome
Int J Clin Exp Pathol 2017;10(2):2030-2035 www.ijcep.com /ISSN:1936-2625/IJCEP0009456 Original Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationHigh expression of fibroblast activation protein is an adverse prognosticator in gastric cancer.
Biomedical Research 2017; 28 (18): 7779-7783 ISSN 0970-938X www.biomedres.info High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer. Hu Song 1, Qi-yu Liu 2, Zhi-wei
More informationPulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis
Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationNumber of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival
Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationTitle: Synuclein Gamma Predicts Poor Clinical Outcome in Colon Cancer with Normal Levels of Carcinoembryonic Antigen
Author's response to reviews Title: Synuclein Gamma Predicts Poor Clinical Outcome in Colon Cancer with Normal Levels of Carcinoembryonic Antigen Authors: Caiyun Liu (liucaiyun23@yahoo.com.cn) Bin Dong
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationLung cancer is now a major cause of death in developed
Original Article New IASLC/ATS/ERS Classification and Invasive Tumor Size are Predictive of Disease Recurrence in Stage I Lung Adenocarcinoma Naoki Yanagawa, MD, PhD,* Satoshi Shiono, MD, PhD, Masami Abiko,
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationStage IB Nonsmall Cell Lung Cancers: Are They All the Same?
ORIGINAL ARTICLES: GENERAL THORACIC GENERAL THORACIC SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article,
More informationVisceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size
GENERAL THORACIC Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD, Neda Kalhor, MD, Wayne L. Hofstetter,
More informationBasaloid Carcinoma of the Lung: A Really Dismal Histologic Variant?
Carcinoma of the Lung: A Really Dismal Histologic Variant? Dae Joon Kim, MD, Kil Dong Kim, MD, Dong Hwan Shin, MD, Jae Y Ro, MD, and Kyung Young Chung, MD Departments of Thoracic and Cardiovascular Surgery,
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationCorrelation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer
Correlation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer X.L. Liu 1, L.D. Liu 2, S.G. Zhang 1, S.D. Dai 3, W.Y. Li 1 and L. Zhang 1 1 Thoracic Surgery,
More informationDetection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell lung Cancer (NSCLC) By CISH Technique
Cancer and Clinical Oncology; Vol. 7, No. 1; 2018 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Detection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell
More informationCorrelation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW
Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,
More informationLUNG CANCER PATHOLOGY: UPDATE ON NEUROENDOCRINE LUNG TUMORS
LUNG CANCER PATHOLOGY: UPDATE ON NEUROENDOCRINE LUNG TUMORS William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering Cancer Center New York, NY PULMONARY NE TUMORS CLASSIFICATION
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationExtent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae
More informationWHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER?
CANCER STAGING TNM and prognosis in CRC WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? Alessandro Lugli, MD Institute of Pathology University of Bern Switzerland Maastricht, June 19
More informationPrognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution
Maruyama et al General Thoracic Surgery Prognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution Riichiroh Maruyama, MD Fumihiro
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationConcurrent Analysis of Human Equilibrative Nucleoside Transporter 1 and Ribonucleotide
1 ORIGINAL ARTICLE Concurrent Analysis of Human Equilibrative Nucleoside Transporter 1 and Ribonucleotide Reductase Subunit 1 Expression Increases Predictive Value for Prognosis in Cholangiocarcinoma Patients
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationLymph node metastasis is the most important prognostic
ORIGINAL ARTICLE Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and III-Tubulin Between Primary Non-small Cell Lung Cancer
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationVisceral pleura invasion (VPI) was adopted as a specific
ORIGINAL ARTICLE Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database Junji Yoshida,
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationSurvival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer
Survival Prediction Models for Estimating the Benefit of Post-Operative Radiation Therapy for Gallbladder Cancer and Lung Cancer Jayashree Kalpathy-Cramer PhD 1, William Hersh, MD 1, Jong Song Kim, PhD
More informationRetrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.
Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman
More informationMinor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis
Ann Surg Oncol (2016) 23:2099 2105 DOI 10.1245/s10434-015-5043-9 ORIGINAL ARTICLE THORACIC ONCOLOGY Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph
More informationACOSOG Thoracic Committee. Kemp H. Kernstine, MD PhD
ACOSOG Thoracic Committee Kemp H. Kernstine, MD PhD ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy Govindan, M.D. Carolyn Reed, MD
More informationAccepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD
Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference:
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationAccepted Manuscript. Adjuvant Chemotherapy in Stage I Lung Cancer: Is More Better? Chuong D. Hoang, MD
Accepted Manuscript Adjuvant Chemotherapy in Stage I Lung Cancer: Is More Better? Chuong D. Hoang, MD PII: S0022-5223(18)31821-X DOI: 10.1016/j.jtcvs.2018.06.069 Reference: YMTC 13198 To appear in: The
More informationInsulinoma-associated protein (INSM1) is a sensitive and specific marker for lung neuroendocrine tumors in cytologic and surgical specimens
Insulinoma-associated protein (INSM1) is a sensitive and specific marker for lung neuroendocrine tumors in cytologic and surgical specimens Kartik Viswanathan, M.D., Ph.D New York Presbyterian - Weill
More informationPathologic Characteristics of Resected Squamous Cell Carcinoma of the Trachea: Prognostic Factors Based on an Analysis of 59 Cases
Pathologic Characteristics of Resected Squamous Cell Carcinoma of the Trachea: Prognostic Factors Based on an Analysis of 59 Cases The Harvard community has made this article openly available. Please share
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationGene expression profiling predicts clinical outcome of prostate cancer. Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M.
SUPPLEMENTARY DATA Gene expression profiling predicts clinical outcome of prostate cancer Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M. Hoffman, William L. Gerald Table of Contents
More informationSurvival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy
Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L. Chen, MD, MBA, Cindy Yu, MD, and Royce
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationEthnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer. Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD,
Ethnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD, MD, Paul Hebert, PhD, Michael C. Iannuzzi, MD, and
More informationEvaluation of cyclin-dependent kinase inhibitor p27 and Bcl-2 protein in nonsmall cell lung cancer
166 Turkish Journal of Cancer Volume 35, No.4, 2005 Evaluation of cyclin-dependent kinase inhibitor p27 and cl-2 protein in nonsmall cell lung cancer LEVENT DERTS Z 1, GÜLY ÖZ L M 2, LKNUR KÜKNER 2, REM
More informationLung cancer is the leading cause of cancer deaths worldwide.
ORIGINAL ARTICLE Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non Small-Cell Lung Cancer Jung-Jyh Hung, MD, PhD,* Wen-Juei Jeng, MD, Wen-Hu
More informationGenetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma
Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma M.J. Wang, Y. Zhu, X.J. Guo and Z.Z. Tian Department of Orthopaedics, Xinxiang Central Hospital, Xinxiang,
More informationEGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More informationIn the mid 1970s, visceral pleural invasion (VPI) was included
ORIGINAL ARTICLE Tumor Invasion of Extralobar Soft Tissue Beyond the Hilar Region Does Not Affect the Prognosis of Surgically Resected Lung Cancer Patients Hajime Otsuka, MD,* Genichiro Ishii, MD, PhD,*
More informationCorrelation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients
1568 Correlation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients LIYING GUO 1, YU ZHANG 2, WEI ZHANG 3 and DILIMINA YILAMU 1 1 Department of
More informationDisclosures. Outline. What IS tumor budding?? Tumor Budding in Colorectal Carcinoma: What, Why, and How. I have nothing to disclose
Tumor Budding in Colorectal Carcinoma: What, Why, and How Disclosures I have nothing to disclose Soo-Jin Cho, MD, PhD Assistant Professor UCSF Dept of Pathology Current Issues in Anatomic Pathology 2017
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationSupplementary Online Content
Supplementary Online Content Bell EH, Pugh SL, McElroy JP, et al. Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era: a correlative analysis based on NRG Oncology
More informationNeuroendocrine Lung Tumors Myers
Diagnosis and Classification of Neuroendocrine Lung Tumors Jeffrey L. Myers, M.D. A. James French Professor Director, Anatomic Pathology & MLabs University of Michigan, Ann Arbor, MI myerjeff@umich.edu
More informationAndrogen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?
Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target? New Frontiers in Urologic Oncology Juan Chipollini, MD Clinical Fellow Department of Genitourinary Oncology Moffitt Cancer
More informationDiagnosis of thoracic endometriosis with immunohistochemistry
Original Article Diagnosis of thoracic endometriosis with immunohistochemistry Yo Kawaguchi 1,2, Jun Hanaoka 1, Yasuhiko Ohshio 1, Tomoyuki Igarashi 1, Keigo Okamoto 1, Ryosuke Kaku 1, Kazuki Hayashi 1,
More informationPleomorphic carcinoma of the lung: which CT findings predict poor prognosis?
Pleomorphic carcinoma of the lung: which CT findings predict poor prognosis? Poster No.: C-1887 Congress: ECR 2015 Type: Scientific Exhibit Authors: A. Fujisaki, T. Aoki, S. Kinoshita, Y. Hayashida, Y.
More informationCorrelation of Vascular Endothelial Growth Factor Expression and Neovascularization with Colorectal Carcinoma: A Pilot Study
Research Article imedpub Journals http://www.imedpub.com Journal of Adenocarcinoma Vol. 1 No. 1:5 DOI: 10.21767/2572-309X.10005 Correlation of Vascular Endothelial Growth Factor Expression and Neovascularization
More informationRare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital
E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.
More informationRevisiting Stage IIIB and IV Non-small Cell Lung Cancer. Analysis of the Surveillance, Epidemiology, and End Results Data
CHEST Revisiting Stage IIIB and IV Non-small Cell Lung Cancer Analysis of the Surveillance, Epidemiology, and End Results Data William N. William, Jr, MD; Heather Y. Lin, PhD; J. Jack Lee, PhD; Scott M.
More informationAlthough ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis
Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,
More informationResults you can trust
PRODUCT I NF OR MAT ION pharmdx Results you can trust The first and only FDA-approved PD-L1 test to assess the magnitude of treatment effect on progression-free survival in melanoma patients from OPDIVO
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationRatio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
More informationPrognostic and predictive biomarkers in
OLOGICAL SCIENCES O DEPT. OF CLINICAL & BIO UNIVERSITY UNIVERSTY OF TORINO Prognostic and predictive biomarkers in early stage NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical &
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationThe projection of short- and long-term survival for. Conditional Survival Among Patients With Carcinoma of the Lung*
Conditional Survival Among Patients With Carcinoma of the Lung* Ray M. Merrill, PhD, MPH; Donald Earl Henson, MD; and Michael Barnes, PhD Objective: One- and 5-year probabilities of survival or death change
More informationGood Old clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers q
European Journal of Cancer 40 (2004) 1837 1841 European Journal of Cancer www.ejconline.com Good Old clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers
More informationLymph node ratio as a prognostic factor in stage III colon cancer
Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com
More informationNeuroendocrine (NE) lung tumors represent a broad
Large Cell Neuroendocrine Carcinoma of the Lung: A 10-Year Clinicopathologic Retrospective Study Massimiliano Paci, MD, Alberto Cavazza, MD, Valerio Annessi, MD, Innocenza Putrino, MD, Guglielmo Ferrari,
More informationAnalysis of Prognosis and Prognostic Factors of Cervical Adenocarcinoma and Adenosqumous Carcinoma of the Cervix
DOI 10.1007/s11805-009-0133-8 133 Analysis of rognosis and rognostic Factors of Cervical Adenocarcinoma and Adenosqumous Carcinoma of the Cervix Guangwen Yuan Lingying Wu Xiaoguang Li Manni Huang Department
More informationThe 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis
The 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis Tieliu Shi tlshi@bio.ecnu.edu.cn The Center for bioinformatics
More informationThe 7th Edition of TNM in Lung Cancer.
10th European Conference Perspectives in Lung Cancer. Brussels, March 2009. The 7th Edition of TNM in Lung Cancer. Peter Goldstraw, Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/55957 holds various files of this Leiden University dissertation Author: Dekker T.J.A. Title: Optimizing breast cancer survival models based on conventional
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationA nonresponding small cell lung cancer combined with adenocarcinoma
Case Report A nonresponding small cell lung cancer combined with adenocarcinoma Hongyang Lu 1,2, Shifeng Yang 3 1 Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (Lung
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationStudy on the expression of MMP-9 and NF-κB proteins in epithelial ovarian cancer tissue and their clinical value
Study on the expression of MMP-9 and NF-κB proteins in epithelial ovarian cancer tissue and their clinical value Shen Wei 1,a, Chen Juan 2, Li Xiurong 1 and Yin Jie 1 1 Department of Obstetrics and Gynecology,
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationLA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II
AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco
More informationMultifocal Lung Cancer
Multifocal Lung Cancer P. De Leyn, MD, PhD Department of Thoracic Surgery University Hospitals Leuven Belgium LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department
More informationLung Cancer in Women: A Different Disease? James J. Stark, MD, FACP
Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine Eastern Virginia Medical
More informationP atients with primary breast cancer have an increased risk of developing contralateral breast cancer1. When
OPEN SUBJECT AREAS: BONE METASTASES BREAST CANCER Received 23 July 2013 Accepted 19 August 2013 Published 5 September 2013 Correspondence and requests for materials should be addressed to C.W.D. (ducaiwen@
More informationXiang Hu*, Liang Cao*, Yi Yu. Introduction
Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang
More informationLung cancer is a prevalent health problem worldwide. It is the leading cause
Prognostic factors in resected stage I non small cell lung cancer with a diameter of 3 cm or less: Visceral pleural invasion did not influence overall and disease-free survival Jung-Jyh Hung, MD, a,b Chien-Ying
More informationUpdates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study
International Journal of Medical Research & Health Sciences Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(7): 14-18 I J M R
More information